A history of immune globulin therapy, from the harvard crash program to monoclonal antibodies

被引：42

作者：

Berger M. ^{[1
]}

机构：

[1] Department of Allergy, Immunology, and Rheumatology, University Hospitals of Cleveland/Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, Cleveland, 44106, OH

来源：

Current Allergy and Asthma Reports | 2002年 / 2卷 / 5期

关键词：

Gamma Globulin; Idiopathic Thrombocytopenic Purpura; Immune Globulin; Kawasaki Disease; Respiratory Syncytial Virus;

D O I：

10.1007/s11882-002-0069-z

中图分类号：

学科分类号：

摘要：

Processes for the large-scale fractionation of human plasma using cold ethanol were initially developed by Edwin Cohn and his colleagues at Harvard to provide albumin as a treatment for shock in World War II. Procedures for further purification of gamma globulins and other proteins precipitating at lower concentrations of ethanol were then developed by Oncley et al. Gamma globulin rapidly replaced convalescent and animal sera for the prevention and treatment of infectious diseases such as measles, hepatitis, and polio, then came into widespread use as replacement therapy in the primary immune deficiencies, which emerged in the antibiotic era of the early 1950s. Although it took 40 years to develop preparations of gamma globulin that could be safely given intravenously, the eventual accomplishment of that goal has led to better treatment of antibody deficiency syndromes and also the wide use of high-dose intravenous immunoglobulin in autoimmune and inflammatory diseases. Those uses continue to expand even as monoclonal antibodies are being introduced for specific infectious diseases in high-risk populations. © 2002, Current Science Inc.

引用

页码：368 / 378

页数：10

共 66 条

[11]

Immunoglobulins: Characteristics and Uses of Intravenous Preparations, (1979)

[12]

Berger M., Cupps T.R., Fauci A.S., Immunoglobulin replacement therapy by slow subcutaneous infusion, Ann Intern Med, 98, pp. 55-56, (1980)

[13]

Gardulf A., Hammarstrom L., Smith C.I.E., Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion, Lancet, 338, pp. 162-166, (1991)

[14]

Gardulf A., Anderson V., Bjorkander J., Et al., Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs, Lancet, 345, pp. 365-369, (1995)

[15]

Stiehm E.R., Casillas A.M., Finkelstein J.Z., Et al., Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product, J Allergy Clin Immunol, 101, pp. 848-849, (1998)

[16]

Ochs H.D., Buckley R.H., Tiller T.L., Et al., Intravenous immunoglobulin therapy of patients with primary immunodeficiency syndromes: efficacy and safety of a new modified immune globulin preparation, Immunoglobulins: Characteristics and Uses of Intravenous Preparations, pp. 9-14, (1979)

[17]

Ammann A.J., Ashman R.F., Buckley R.H., Et al., Use of intravenous g-globulin in antibody immunodeficiency: Results of a multicenter controlled trial, Clin Immunol Immunopathol, 22, pp. 60-67, (1982)

[18]

Pirofsky B., Anderson C.J., Bardana E.J., Therapeutic and detrimental effects of intravenous immunoglobulin therapy, Immunoglobulins: Characteristics and Uses of Intravenous Preparations, pp. 15-22, (1979)

[19]

Ochs H.D., Buckley R.N., Pirofsky B., Et al., Safety and patient acceptability of intravenous immune globulin in 10% maltose, Lancet, 2, pp. 1158-1159, (1980)

[20]

Barandun S., Morell A., Skvaril F., Clinical experiences with immunoglobulin for intravenous use, Immunoglobulins: Characteristics and Uses of Intravenous Preparations, pp. 31-36, (1979)

← 1 2 3 4 5 6 7 →